



1/24/06


DOCKET NO.: 10248.70024US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Adams et al.
Serial No.: 10/616,409
Confirmation No.: 9289
Filed: July 9, 2003
For: BOROPROLINE COMPOUND COMBINATION THERAPY
Examiner: Brandon J. Fetterolf
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17th day of July, 2006.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$180 is enclosed to cover the filing fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:



Maria A. Trevisan, Reg. No.: 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: 10248.70024US00

Date: July 17, 2006

xNDDx




DOCKET NO.: I0248.70024US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Adams et al.
Serial No.: 10/616,409
Confirmation No.: 9289
Filed: July 9, 2003
For: BOROPROLINE COMPOUND COMBINATION
THERAPY
Examiner: Brandon J. Fetterolf
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17th day of July, 2006.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

1005837.1

07/21/2006 GWORDOF1 00000086 10616409

01 FC:1806

180.00 OP

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
11/474,929	06-26-2006	Wallner et al.	*I0248.70016US02
11/476,524	06-28-2006	Wallner et al.	*I0248.70020US02

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,


By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: I0248.70024US00
Date: July 17, 2006
xNDDx.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
	FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
	APPLICANT: Adams et al.			
	GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf	
Sheet		of	6	



U.S. PATENT DOCUMENTS

Examiner's Initials #	No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,318,904		Shaw et al.	03-09-1982
		4,652,552		Kettner et al.	03-24-1987
		4,963,655		Kinder et al.	10-16-1990
		5,093,477		Mölling et al.	03-03-1992
		5,187,157		Kettner et al.	02-16-1993
		5,242,904		Kettner et al.	09-07-1993
		5,250,720		Kettner et al.	10-05-1993
		5,624,894		Bodor	04-29-1997
		5,939,560		Jenkins et al.	08-17-1999
		6,201,132	B1	Jenkins et al.	03-13-2001
		6,265,551		Duke-Cohan et al.	07-24-2001
		6,303,661	B1	Demuth et al.	10-16-2001
		6,500,804		Demuth et al.	12-31-2002
		6,548,481	B1	Demuth et al.	04-15-2003
		6,803,357	B1	Bachovchin et al.	10-12-2004
		6,844,180		Oi et al.	01-18-2005
		6,881,564		Abbott et al.	04-19-2005
		6,890,904	B1	Wallner et al.	05-10-2005
		6,890,905	B2	Demuth et al.	05-10-2005
		6,946,480		Demuth et al.	09-20-2005
		6,949,514		Wallner et al.	09-27-2005
		6,979,697		Wallner	12-27-2005
		7,067,489	B2	Wallner et al.	06-27-2006
		2002-0006899	A1	Pospisilik et al.	01-17-2002
		2002-0198242	A1	Demuth et al.	12-26-2002
		2003-0008905	A1	Demuth et al.	01-09-2003
		2003-0119736	A1	Demuth et al.	06-26-2003
		2003-0119750	A1	Demuth et al.	06-26-2003
		2003-0134802	A1	Demuth et al.	07-17-2003
		2003-0135023	A1	Demuth et al.	07-17-2003
		2003-0148961	A1	Heiser et al.	08-07-2003
		2003-0153509	A1	Bachovchin et al.	08-14-2003
		2003-0162820	A1	Demuth et al.	08-28-2003

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: I0248.70024US00		
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289		
				APPLICANT: Adams et al.				
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf		
Sheet	2	of	6					

		2003-0176357	A1	Pospisilik et al.	09-18-2003
		2003-0220267	A1	Matteson et al.	11-27-2003
		2004-0053369	A1	Abbott et al.	03-18-2004
		2004-0077601	A1	Adams et al.	04-22-2004
		2004-0167191	A1	Demuth et al.	08-26-2004
		2004-0176307	A1	Bachovchin et al.	09-09-2004
		2004-0229820	A1	Bachovchin et al.	11-18-2004
		2004-0229848	A1	Demuth et al.	11-18-2004
		2005-0008644	A1	Huber et al.	01-13-2005
		2005-0043299	A1	Evans et al.	02-24-2005
		2005-0084490	A1	Adams et al.	04-21-2005
		2005-0171025	A1	Von Hoersten et al.	08-04-2005
		2005-0202027	A1	Bachovchin	09-15-2005
		2005-0203027	A1	Bachovchin et al.	09-15-2005
		2005-0209249	A1	Akritopoulou-Zanze et al.	09-22-2005
		2005-0215603	A1	Akritopoulou-Zanze et al.	09-29-2005
		2005-0215784	A1	Madar et al.	09-29-2005
		2005-0272703	A1	Wallner et al.	12-08-2005
		2006-0052310	A1	Wallner et al.	03-09-2006
		2006-0063719	A1	Jesson et al.	03-23-2006
		2006-0094693	A1	Aziz et al.	05-04-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials [#]	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		AU	729369		Ludwig Institute for Cancer Research	02-01-2001	
		DD	158 109		Martin-Luther-Universitaet Halle Wittenberg	12-29-1982	Abstract
		DD	296075	A5	Martin-Luther-Universitaet Halle Wittenberg	11-21-1991	Abstract
		EP	0 471 651	A2	Sandoz Ltd.	02-19-1992	Abstract
		NZ	335543		Ludwig Institute for Cancer Research	03-30-2001	
		WO	95/12618	A1	Eurogenetics N.V.	05-11-1995	
		WO	95/29233	A1	Ludwig Institute for Cancer Research	11-02-1995	
		WO	95/29691	A1	Georgia Tech Research Corporation	11-09-1995	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00			
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289			
				APPLICANT: Adams et al.					
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf			
Sheet	3	of	6						

		WO	95/34538	A2	Univeristaire Instelling Antwerpen	12-21-1995	
		WO	97/34927	A1	Ludwig Institute for Cancer Research	09-25-1997	
		WO	98/25644	A1	1149336 Ontario Inc.	06-18-1998	
		WO	99/47152	A2	Sloan Kettering Institute for Cancer Research	09-23-1999	
		WO	01/79473	A2	Millennium Pharmaceuticals, Inc.	10-25-2001	
		WO	01/98468	A2	Incyte Genomics, Inc.	12-27-2001	
		WO	02/31134	A2	Ferring BV	04-18-2002	
		WO	02/051992	A2	Millennium Pharmaceuticals, Inc.	07-04-2002	
		WO	03/092605	A2	Trustees of Tufts College	11-13-2003	
		WO	2005/071073	A1	Point Therapeutics, Inc.	08-04-2005	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ABBOTT et al., Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 1999 Sep 24;458(3):278-84.	
		ABBOTT et al., Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000 Oct;267(20):6140-50.	
		ADAMS et al., "Enhanced Anti-Tumor Activity of Dipeptidyl Peptidase Inhibitor PT-100 in Combination with Chemotherapy in Mice," American Association of Cancer Research (AACR) Annual Meeting, Orlando, Florida, March 27-31, 2004, Poster 3820. Re-submission.	
		ANSORGE et al., CD26/dipeptidyl peptidase IV in lymphocyte growth regulation. Adv Exp Med Biol. 1997;421:127-40. Abstract Only.	
		ARIGA et al., Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer. 2001 Jan 20;95(1):67-72.	
		AYTAC et al., Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. 2001 Oct 1;61(19):7204-10.	
		BENSAADI et al., Modulation of enzymatic activities during spontaneous and induced differentiation in a human pancreatic adenocarcinoma cell line CAPAN-1. Int J Pancreatol. 1989 May;4(4):391-406. Abstract Only.	
		BRISTOL et al., Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol. 1992 Jul 15;149(2):367-72.	
		BRISTOL et al., Inhibition of CD26 enzyme activity with pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood. 1995 Jun 15;85(12):3602-9.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00		
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289		
				APPLICANT: Adams et al.				
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf		
Sheet	4	of	6					

		BUSEK et al., Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. <i>Int J Biochem Cell Biol.</i> 2004 Mar;36(3):408-21.	
		CHEN et al., Dipeptidyl peptidase IV gene family. The DPIV family. <i>Adv Exp Med Biol.</i> 2003;524:79-86.	
		CHENG et al., Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. <i>Cancer Res.</i> 2002 Aug 15;62(16):4767-72.	
		COUTTS et al., Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids. <i>Tetrahedron Letts.</i> 1994;35(29):5109-12.	
		COUTTS et al., Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. <i>J Med Chem.</i> 1996 May 10;39(10):2087-94.	
		CUNNINGHAM et al., "Phase 2 Trial of Talabostat and Docetaxel in Patients with Stage IIIB/IV NSCLC," American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Florida, May 17, 2005, Poster 7120. Re-submission.	
		FLEISHER et al., Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. <i>J Immunol.</i> 1988 Aug 15;141(4):1103-7. Abstract Only.	
		FLENTKE et al., Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. <i>Proc Natl Acad Sci U S A.</i> 1991 Feb 15;88(4):1556-9.	
		GARIN-CHESA et al., Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. <i>Proc Natl Acad Sci U S A.</i> 1990 Sep;87(18):7235-9.	
		GIBSON et al., A practical synthesis of L-Valyl-pyrrolidine-(2R)-boronic acid: Efficient recycling of the costly chiral auxiliary (+)-Pinanediol. <i>Org Proc Res & Dev.</i> 2002;6:814-16.	
		GOLDSTEIN et al., Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform. <i>J Biol Chem.</i> 2000 Jan 28;275(4):2554-9.	
		GOLDSTEIN et al., Molecular cloning of seprase: a serine integral membrane protease from human melanoma. <i>Biochim Biophys Acta.</i> 1997 Jul 10;1361(1):11-9.	
		GORRELL et al., Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. <i>Clin Sci (Lond).</i> 2005 Apr;108(4):277-92.	
		GÜNTHER et al., Solution structures of the DP IV (CD26) inhibitor Val-BoroPro determined by NMR spectroscopy. <i>Magn Reson Chem.</i> 1995;33:959-70.	
		GUTHEIL et al., Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. <i>Biochemistry.</i> 1993 Aug 31;32(34):8723-31.	
		HEGEN et al., Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. <i>Cell Immunol.</i> 1993 Feb;146(2):249-60. Abstract Only.	
		HEGEN et al., Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. <i>Immunobiology.</i> 1993 Dec;189(5):483-93. Abstract Only.	
		HEINS et al., Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from <i>Flavobacterium meningosepticum</i> . <i>Biochim Biophys Acta.</i> 1988 May 18;954(2):161-9. Abstract Only.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: I0248.70024US00		
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289		
				APPLICANT: Adams et al.				
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf		
Sheet	5	of	6					

		HILDEBRANDT et al., Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001 Oct;36(10):1067-72. Abstract Only.	
		HOFFMANN et al., Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 1993 Dec 20;336(1):61-4.	
		KHAN et al., "Phase 2 Study of Talabostat and Rituximab in Patients with Advanced CLL Previously Treated with Rituximab/Fludarabine." American Society of Hematology Annual Meeting. December 2005. Poster 2125.	
		LOKSHINA et al., Proteolytic enzymes in human leukemic lymphoid cells. III. Aminopeptidases, angiotensin-converting enzyme, and its inhibitor in cells of different immunological phenotype. Biochemistry (Mosc). 1999 Apr;64(4):448-55. Abstract Only.	
		MATHEW et al., The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics. 1995 Jan 1;25(1):335-7.	
		MATTESON et al., Synthesis and properties of pinanediol .alpha.-amido boronic esters. Organometallics. 1984;3(8):1284-8.	
		MITTRUCKER et al., The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol. 1995 Jan;25(1):295-7. Abstract Only.	
		MORIMOTO et al., IF7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol. 1989 Dec 1;143(11):3430-9. Erratum in: J Immunol 1990 Mar 1;144(5):2027.	
		MORRISON et al., A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993 Apr 1;177(4):1135-43.	
		NEMUNAITIS et al., "A Phase 1 Trial of Talabostat (PT-100) in Patients Receiving Myelosuppressive Chemotherapy," American Society of Clinical Oncology (ASCO) Annual Meeting, New Orleans, Louisiana, June 5-8, 2004, Poster 2572. Re-submission.	
		NIEDERMEYER et al., Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer. 1997 May 2;71(3):383-9.	
		NIEDERMEYER et al., Mouse fibroblast-activation protein--conserved Fap gene organization and biochemical function as a serine protease. Eur J Biochem. 1998 Jun 15;254(3):650-4.	
		NOVELLI et al., Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol. 1996 Jun;134(6):1052-6. Abstract Only.	
		ORAVECZ et al., Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 1997 Dec 1;186(11):1865-72.	
		PARK et al., Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999 Dec 17;274(51):36505-12.	
		PETHIYAGODA et al., Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis. 2000;18(5):391-400. Abstract Only.	
		PINEIRO-SANCHEZ et al., Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 1997 Mar 21;272(12):7595-601.	
		RETTIG et al., Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993 Jul 15;53(14):3327-35.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409	ATTY. DOCKET NO.: 10248.70024US00
				FILING DATE: July 9, 2003	CONFIRMATION NO.: 9289
				APPLICANT: Adams et al.	
				GROUP ART UNIT: 1642	EXAMINER: Brandon J. Fetterolf
Sheet	6	of	6		

		RETTIG et al., Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 1994 Aug 1;58(3):385-92.	
		RETTIG et al., Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A. 1988 May;85(9):3110-4.	
		ROSENBLUM et al., Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 2003 Aug;7(4):496-504.	
		SUDMEIER et al., Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. Biochemistry. 1994 Oct 18;33(41):12427-38.	
		UNDERWOOD et al., Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem. 1999 Nov 26;274(48):34053-8.	
		WATSON et al., Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med. 1979 Dec 1;150(6):1510-9. Abstract Only.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.